Profile
ARDS VRTX REGN VRNA ARGX ALNY
Company Name Aridis Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $8.92K $116.75B $76.56B $72.68B $52.08B $51.68B
Employees 0.04K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Vu L. Truong Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
ARDS VRTX REGN VRNA ARGX ALNY
Quant Rating Score 1 4 4 1 4 3
Quant Rating Strong Sell Buy Buy Strong Sell Buy Neutral
Trading
ARDS VRTX REGN VRNA ARGX ALNY
Last Close $0.0002 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 - $513.76 $788 $106.91 $929.61 $491.09
Low 52 - $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High 0 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 0 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
ARDS VRTX REGN VRNA ARGX ALNY
1 Month Return 0 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return 100 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 100 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 100 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 100 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 100 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ARDS VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.47 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -355.21 % 9.76 % 4.25 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 6.06 % - - -
Profitability
ARDS VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM - 86.28 % 85.39 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -209.25 % 14.78 % 11.4 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM 164.69 % 19.62 % 15.31 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM 135.09 % 19.59 % 10.32 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 101.24 % 82.61 % 88.98 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 101.26 % 111.4 % 139.5 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM - 34.06 % 25.89 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -475.15 % 202.64 % 187.43 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM - 6.02 2.51 1.93 1.91 3.33
Payables Turnover TTM - 0.4 2.3 2.37 0.9 4.37
Inventory Turnover TTM - 0.99 0.64 0.94 2.26 6.82
Fixed Asset Turnover TTM - 388.59 % 284.82 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM - 47.15 % 35.47 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -1.55 14.55 48.94 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -1.56 13.06 40.09 -0.85 5.58 1.68
Cash Per Share TTM 25.97 % 2459.7 % 8148.65 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 35.59 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.28 % 89.76 % 81.92 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -475.15 % 202.64 % 187.43 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM - 34.99 18.43 -995.27 133.11 233.46
Price To Operating Cash Flows Ratio TTM - 31.28 15.15 -126.33 152.03 193.4
Price Cash Flow Ratio TTM - 31.28 15.15 -126.33 152.03 193.4
Income Statement (TTM)
ARDS VRTX REGN VRNA ARGX ALNY
Revenue $0B $11.02B $14.2B $0.03B $2.19B $2.25B
Gross Profit $0B $9.49B $12.23B $0.03B $1.96B $1.92B
Gross Profit Ratio 0% 86.11% 86.13% 93.89% 89.62% 85.62%
EBITDA $-0.03B $0.49B $5.32B $-0.12B $0.11B $-0.18B
Net Income $-0.03B $-0.54B $4.41B $-0.14B $0.83B $-0.28B
EPS Diluted -1.64 -2.08 38.34 -1.73 12.78 -2.18
Balance Sheet (MRQ)
ARDS VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.7B $0.12B $0.03B $2.59B
Total Liabilities $0.04B $6.12B $8.41B $0.27B $0.7B $4.17B
Total Equity $-0.02B $16.41B $29.35B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $15.42B $0.02B $1.93B $1.73B
Total Debt $0.01B $1.75B $2.7B $0.12B $0.04B $2.74B
Total Assets $0.01B $22.53B $37.76B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
ARDS VRTX REGN VRNA ARGX ALNY
Net Income $-0.03B $-0.54B $4.41B $-0.17B $0.83B $-0.28B
Inventory $0B $-0.52B $-0.62B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.03B $-0.49B $4.42B $-0.12B $-0.08B $-0.01B
Capital Expenditure $-0B $-0.3B $-0.76B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 28.72
AARD Aardvark Therapeutics, Inc. Common Stock 13.575
ABCL AbCellera Biologics Inc. 3.465
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.92
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.105
ABPWW 0.014
ABSI Absci Corporation 3.55
ABUS Arbutus Biopharma Corporation 4.58
ABVC ABVC BioPharma, Inc. 2.045
ABVX Abivax SA American Depositary Shares 110.73
ACAD ACADIA Pharmaceuticals Inc. 27.177
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.4812
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.33
ACIU AC Immune SA 3.0932
ETFs With Exposure to ARDS
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 332.225
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 146.89
Unlock